In a similar phase 2 trial involving trametinib, another MEK inhibitor, there was no survival benefit of the combination with docetaxel over docetaxel alone among previously treated patients with KRAS-mutant NSCLC [60]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.